An amendment to this paper has been published and can be accessed via the original article.
Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis (BMC Nephrology, (2021), 22, 1, (5), 10.1186/s12882-020-02190-0) / Gackler A.; Schonermarck U.; Dobronravov V.; La Manna G.; Denker A.; Liu P.; Vinogradova M.; Yoon S.-S.; Praga M.. - In: BMC NEPHROLOGY. - ISSN 1471-2369. - ELETTRONICO. - 22:(2021), pp. 1-1. [10.1186/s12882-021-02242-z]
Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis (BMC Nephrology, (2021), 22, 1, (5), 10.1186/s12882-020-02190-0)
La Manna G.;
2021
Abstract
An amendment to this paper has been published and can be accessed via the original article.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Gäckler A et al_BMC Nephrology 2021_correction.pdf
accesso aperto
Descrizione: Gäckler A et al_BMC Nephrology 2021_correction
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
193 kB
Formato
Adobe PDF
|
193 kB | Adobe PDF | Visualizza/Apri |
|
Supplementary materials.zip
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per accesso libero gratuito
Dimensione
686.46 kB
Formato
Zip File
|
686.46 kB | Zip File | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
